Through the agreement, Aspen will pay about $239 million to obtain the rights to GSK’s six anesthetic drugs — Ultiva, Nimbex, Tracrium, Mivacron and Anectine. Aspen is also eligible to earn up to about $133 million in milestone payments.
GSK previously sold the U.S. and Canadian rights to the six anesthetics and earned about $46 million for the drugs in the first half of 2016.
Aspen bought a majority of GSK’s thrombosis drug portfolio in 2013, with the exception of certain areas, including China, India and Pakistan. The South African drugmaker will now acquire GSK’s remaining rights to the drug.
Aspen and GSK will also end collaboration efforts in sub-Saharan Africa, with each company separately marketing their portfolios in the area.
More articles on supply chain:
FDA investigates St. Jude Medical’s cardiac devices for potential security flaws
4 drug companies on Fortune’s ‘Change the World’ list
Pfizer CEO: Clinton’s plan to lower drug costs is bad for consumers
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
